Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art
Uncommon (ucEGFRmuts) and rare epidermal growth factor receptor (<i>EGFR</i>) mutations account for 10–15% of diagnosed cases and consist of a heterogeneous group represented by several clusters within exons 18–21 (e.g., exon 18 point mutations, exon 21 L861X, exon 20 S768I), as well as...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/7/1331 |
| _version_ | 1797212803722903552 |
|---|---|
| author | Federico Pio Fabrizio Ilaria Attili Filippo de Marinis |
| author_facet | Federico Pio Fabrizio Ilaria Attili Filippo de Marinis |
| author_sort | Federico Pio Fabrizio |
| collection | DOAJ |
| description | Uncommon (ucEGFRmuts) and rare epidermal growth factor receptor (<i>EGFR</i>) mutations account for 10–15% of diagnosed cases and consist of a heterogeneous group represented by several clusters within exons 18–21 (e.g., exon 18 point mutations, exon 21 L861X, exon 20 S768I), as well as exon 20 insertions (Ex20ins). Their incidence is under molecular and clinical investigation following recent findings that reported an increase of sensitivity and specificity of next-generation sequencing (NGS) methods. Consequently, their detection allows for the selection of emerging treatment options to significantly improve patients’ outcomes in these particular subgroups of <i>EGFR</i>-mutated advanced non-small cell lung cancer (NSCLC). Specifically, this commentary is focused on the notable progress of the Phase 3 PAPILLON study that showed primary efficacy results from amivantamab, a bispecific antibody with specific binding and affinity to extracellular domains of EGFR and MET, plus chemotherapy in the first-line setting for EGFR exon 20 insertion–mutated advanced or metastatic NSCLC patients, as compared with chemotherapy alone, thus becoming the new standard of care in this group of patients. |
| first_indexed | 2024-04-24T10:48:12Z |
| format | Article |
| id | doaj.art-c3146ffb663c421694202e048dcc0d49 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-04-24T10:48:12Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c3146ffb663c421694202e048dcc0d492024-04-12T13:16:03ZengMDPI AGCancers2072-66942024-03-01167133110.3390/cancers16071331Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the ArtFederico Pio Fabrizio0Ilaria Attili1Filippo de Marinis2Laboratory of Oncology, Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, ItalyDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, 20141 Milan, ItalyDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, 20141 Milan, ItalyUncommon (ucEGFRmuts) and rare epidermal growth factor receptor (<i>EGFR</i>) mutations account for 10–15% of diagnosed cases and consist of a heterogeneous group represented by several clusters within exons 18–21 (e.g., exon 18 point mutations, exon 21 L861X, exon 20 S768I), as well as exon 20 insertions (Ex20ins). Their incidence is under molecular and clinical investigation following recent findings that reported an increase of sensitivity and specificity of next-generation sequencing (NGS) methods. Consequently, their detection allows for the selection of emerging treatment options to significantly improve patients’ outcomes in these particular subgroups of <i>EGFR</i>-mutated advanced non-small cell lung cancer (NSCLC). Specifically, this commentary is focused on the notable progress of the Phase 3 PAPILLON study that showed primary efficacy results from amivantamab, a bispecific antibody with specific binding and affinity to extracellular domains of EGFR and MET, plus chemotherapy in the first-line setting for EGFR exon 20 insertion–mutated advanced or metastatic NSCLC patients, as compared with chemotherapy alone, thus becoming the new standard of care in this group of patients.https://www.mdpi.com/2072-6694/16/7/1331EGFRNSCLCamivantamab |
| spellingShingle | Federico Pio Fabrizio Ilaria Attili Filippo de Marinis Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art Cancers EGFR NSCLC amivantamab |
| title | Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art |
| title_full | Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art |
| title_fullStr | Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art |
| title_full_unstemmed | Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art |
| title_short | Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art |
| title_sort | uncommon and rare i egfr i mutations in non small cell lung cancer patients with a focus on exon 20 insertions and the phase 3 papillon trial the state of the art |
| topic | EGFR NSCLC amivantamab |
| url | https://www.mdpi.com/2072-6694/16/7/1331 |
| work_keys_str_mv | AT federicopiofabrizio uncommonandrareiegfrimutationsinnonsmallcelllungcancerpatientswithafocusonexon20insertionsandthephase3papillontrialthestateoftheart AT ilariaattili uncommonandrareiegfrimutationsinnonsmallcelllungcancerpatientswithafocusonexon20insertionsandthephase3papillontrialthestateoftheart AT filippodemarinis uncommonandrareiegfrimutationsinnonsmallcelllungcancerpatientswithafocusonexon20insertionsandthephase3papillontrialthestateoftheart |